Drug interaction: Omeprazole and phenprocoumon

被引：13

作者：

Enderle C. ^{[1
]}

Müller W. ^{[2
]}

Grass U. ^{[3
]}

机构：

[1] 88499 Riedlingen

[2] 31737 Rinteln

[3] 78351 Bodman-Ludwigshafen

来源：

BMC Gastroenterology | / 1卷 / 1期

关键词：

Omeprazole; International Normalise Ratio; Irbesartan; Anticoagulant Activity; Dipyrone;

D O I：

10.1186/1471-230X-1-2

中图分类号：

学科分类号：

摘要：

Background: Oral anticoagulants like the coumarin derivatives are characterised by a particularly narrow therapeutic range. Any interfering co-medication can pose a challenge to establishing a stable anticoagulant dosage regimen and thus present a serious risk for the patient. Here we describe two cases of patients on anticoagulant therapy that suggest possible drug interactions between phenprocoumon and the proton pump inhibitor omeprazole. Results: In both patients, the International Normalised Ratio (INR) increased beyond the therapeutic range after they were given omeprazole for the treatment of gastrointestinal symptoms. The INR returned to therapeutic levels after the phenprocoumon dose was reduced (Case 1) and omeprazole discontinued (Case 2). Conclusions: The increased anticoagulant activity of phenprocoumon observed in the two described cases and the known interaction potential of omeprazole suggest that the clearance of phenprocoumon may have been reduced due to competitive inhibition of its degradation by omeprazole. Drug interactions may be one of the reasons for the difficulties encountered with some patients in establishing a stable anticoagulant therapy. Physicians should carefully review any concurrently used medication and if possible opt for drugs with a low interaction potential. © 2001 Enderle et al, licensee BioMed Central Ltd.

引用

共 14 条

[1]

Freedman M.D., Olatidoye A.G., Clinical significant drug interactions with the oral anticoagulants, Drug Saf., 10, pp. 381-394, (1994)

[2]

Landefeld C.S., Beyth R.J., Anticoagulation related bleeding: Clinical epidemiology, prediction and prevention, Am. J. Med., 95, pp. 315-328, (1993)

[3]

Andersson T., Pharmacokinetics, metabolism and interactions of acid pump inhibitors, Clin. Pharmacokinet., 31, pp. 9-28, (1996)

[4]

Meyer U.A., Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions, Yale J. Biol. Med., 69, pp. 203-209, (1996)

[5]

Kerremans A.L.M., Cytochrome P450 isoenzymes - Importance for the internist, Netherlands J. Med., 48, pp. 237-243, (1996)

[6]

Wrigton S.A., Stevens J.C., The human hepatic cytochromes P450 involved in drug metabolism, Crit. Rev. Toxicol., 22, 1, pp. 1-22, (1992)

[7]

Newton D.J., Wang R.W., Lu A.Y.H., Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes, Drug Metab. Dispos., 23, pp. 154-158, (1995)

[8]

Ko J.-W., Sukhova N., Thacker D., Chen P., Flockhart D.A., Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms, Drug Metab. Dispos., 25, pp. 853-862, (1997)

[9]

He M., Korzekawa K.R., Jones J.P., Rettie A.E., Trager W.F., Structural forms of phenprocoumon and warfarin that are metabolised at the active site of CYP2C9, Arch. Biochem. Biophys., 372, pp. 16-28, (1999)

[10]

Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P., Effect of omeprazole treatment on diazepam levels in slow versus normal rapid metabolizers of omeprazole, Clin. Pharmacol. Ther., 47, pp. 79-85, (1990)

← 1 2 →